Oppenheimer & Co. Inc. Purchases New Shares in Repligen Co. (NASDAQ:RGEN)

Oppenheimer & Co. Inc. purchased a new stake in Repligen Co. (NASDAQ:RGEN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,500 shares of the biotechnology company’s stock, valued at approximately $216,000.

A number of other institutional investors and hedge funds have also bought and sold shares of RGEN. Amalgamated Bank increased its position in shares of Repligen by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,114 shares of the biotechnology company’s stock valued at $3,615,000 after purchasing an additional 238 shares during the last quarter. Keeler Thomas Management LLC increased its position in shares of Repligen by 68.9% during the 4th quarter. Keeler Thomas Management LLC now owns 8,979 shares of the biotechnology company’s stock valued at $1,294,000 after purchasing an additional 3,662 shares during the last quarter. Handelsbanken Fonder AB increased its position in shares of Repligen by 8.9% during the 4th quarter. Handelsbanken Fonder AB now owns 14,633 shares of the biotechnology company’s stock valued at $2,106,000 after purchasing an additional 1,200 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 129 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock valued at $83,693,000 after purchasing an additional 14,398 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 2.8 %

Shares of NASDAQ RGEN opened at $155.70 on Monday. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $203.13. The business has a 50-day simple moving average of $157.23 and a two-hundred day simple moving average of $148.59. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.72 billion, a P/E ratio of -305.29, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $181.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.